MedTrace Logo

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

NCT03639766 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-06-30

Study results available
· View outcomes & findings →

Summary

This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.

Conditions

  • Raynaud Phenomenon

Interventions

DRUG

AbobotulinumtoxinA

AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution

OTHER

Saline solution

Non-bacteriostatic saline solution

Sponsors & Collaborators

  • University of Central Florida

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2020-01-31
Completion
2020-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639766 on ClinicalTrials.gov